Tests NCR201 cell therapy in people with Parkinson's disease
Tests NCR201 cells, made from stem cells, in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Key facts
- Where
- Hefei, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT06978920, who can take part
Where in China
- The First Affiliated Hospital of USTCHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nuwacell Biotechnologies Co., Ltd.
- Trial code
- NCT06978920
- Record updated
- 1 August 2025
- Original description
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.Read full original descriptionShow less
A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Inclusion: Ages between 40 and 75 years; Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria; Disease history over 5 years; Stable dose of dopamine treatment; Able to undergo PET/CT/MRI detection.
Exclusion: Patients who have previously undergone brain surgery; Past use of stem cell therapy or participation in stem cell clinical research; Cognitive impairment; History of mental disorders; Patients with other serious systemic diseases; Past or current metastatic malignant tumors.